A brief report found that a need for prior authorization affected biologic approval wait times for patients with psoriasis, especially those with private insurance.
Insurance type and a need for prior authorization were identified as factors that impact wait times for patients with psoriasis who are prescribed biologics for treatment, according to a new report published in Archives of Dermatological Research.
Psoriasis is thought to affect up to 11.4% of adults globally, and low socioeconomic status has been associated with a higher prevalence of severe disease. The most effective treatment for moderate to severe psoriasis includes biologics, but many patients with psoriasis and psoriatic arthritis face delays in care due to a need for insurance approval and prior authorization for biologics.
Researchers assessed biologic approval wait times using medical records from 101 biologic-naïve patients with psoriasis at the University of Miami Health System between 2000 and 2019. Main variables of interest included patient race/ethnicity, provider specialty, and insurance type.
A need for prior authorization was significantly associated with long waits for approval (P = 2.4 x 10−5) in a multilinear regression model, but race/ethnicity was not a significant factor in patient wait times in this study. Non-Hispanic White patients waited a mean of 29.7 days for insurance approval, and African American or Hispanic patients waited a mean of 27.2 days.
There were significant differences in same-day approvals depending on the type of insurance the patients had. Those with health maintenance organization (HMO) carriers received same-day approval 23.7% of the time; preferred provider organization (PPO) carriers, 11.5%; Medicare carriers, 63%; and Medicaid carriers, 40%. Mean wait times were 7.3, 11.3, 37, and 41.3 days for Medicare, Medicaid, PPO, and HMO carriers, respectively.
In the multilinear regression model, Medicaid was also predictive of approval wait time (P < .05) in addition to the need for prior authorization. Overall, patients who had private insurance waited the longest for biologic approval, regardless of whether they were PPO or HMO carriers. There was no difference in the type of biologic prescribed based on insurance type.
Study limitations included its retrospective nature, which prevented assessment of variables such as income, education level, or other aspects of socioeconomic status. The cohort was also largely White-Hispanic, limiting the study’s generalizability to a national population. The authors noted that differences in prescriber preference and certain insurance policies could also drive wait time differences, but 71% of the patients in the study cohort were prescribed either adalimumab or etanercept—both of which are usually preferred by insurance companies.
“Our results did not show a difference in insurance approval times for biologics based on race/ethnicity,” the authors concluded. “However, we found that patients with private insurance carriers had fewer same-day approvals and had to wait longer than 7 days more frequently than those with government-funded plans.”
Reference
Vazquez T, Forouzandeh M, Lin D, et al. Insurance delays in the approval of biologic medications for patients with psoriasis and psoriatic arthritis. Arch Dermatol Res. Published online November 14, 2022. doi:10.1007/s00403-022-02457-6
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Congress Urged to Repeal Comstock Act Threatening Reproductive Rights and Public Health
May 16th 2024In a joint letter addressed to Congress, Healthcare Across Borders, Take Back the Court Action Fund, and UltraViolet Action called out the resurgence of the Comstock Act, urging immediate action to repeal this century-old law that threatens reproductive rights and public health in the US.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Congress Urged to Repeal Comstock Act Threatening Reproductive Rights and Public Health
May 16th 2024In a joint letter addressed to Congress, Healthcare Across Borders, Take Back the Court Action Fund, and UltraViolet Action called out the resurgence of the Comstock Act, urging immediate action to repeal this century-old law that threatens reproductive rights and public health in the US.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More
2 Commerce Drive
Cranbury, NJ 08512